Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
PGNX > SEC Filings for PGNX > Form 8-K on 25-Nov-2013All Recent SEC Filings

Show all filings for PROGENICS PHARMACEUTICALS INC

Form 8-K for PROGENICS PHARMACEUTICALS INC


25-Nov-2013

Other Events, Financial Statements and Exhibits


Item 8.01. Other Events.

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) today announced that it is resuming a phase 2b clinical study of safety and efficacy of a novel targeted radiotherapy, AzedraTM, in patients suffering from pheochromocytomas. The company plans for patient recruitment to continue in the trial, which its Molecular Insight Pharmaceuticals subsidiary suspended in late 2010, after making drug supply manufacturing arrangements for the trial.

A copy of the company's press release is included in this Report as Exhibit 99.1, and the information contained therein is incorporated into this Item 8.01 by this reference.



Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

99.1 Press Release issued November 25, 2013.


  Add PGNX to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for PGNX - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.